Market Closed -
Nasdaq
02:00:00 27/04/2024 am IST
5-day change
1st Jan Change
4.37
USD
-12.60%
-36.32%
-64.58%
Sales 2024 *
5.02M
418M
Sales 2025 *
8.17M
681M
Capitalization
3.77M
314M
Net income 2024 *
-12M
-1B
Net income 2025 *
-13M
-1.08B
EV / Sales 2024 *
0.75
x
Net cash position
2024
*
-
0
Net cash position
2025
*
-
0
EV / Sales 2025 *
0.46
x P/E ratio 2024 *
-0.34
x
P/E ratio 2025 *
-0.41
x
Employees
54
Yield 2024 *
-
Yield 2025 *
-
Free-Float
87.56%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Applied DNA Sciences, Inc. Receives Contract by HDT Bio for Rapid Vaccine Development Program
25/04
CI
Certain Warrants of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.
03/04
CI
Certain Options of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.
03/04
CI
Certain Common Stock of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.
03/04
CI
Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress
14/03
CI
Applied DNA Sciences Files Prospectus for Potential Secondary Stock Offerings
12/03
MT
Transcript : Applied DNA Sciences, Inc., Q1 2024 Earnings Call, Feb 08, 2024
09/02
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q1 Revenue $891,164
09/02
MT
Applied DNA Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
09/02
CI
Applied DNA Sciences, Inc. Announces Joint Development Agreement to Integrate Linea IVT Platform into CDMO Kudo Biotechnology?s mRNA Manufacturing Workflow
14/12
CI
HC Wainwright Cuts Price Target on Applied DNA Sciences to $2 From $4, Keeps Buy Rating
08/12
MT
Transcript : Applied DNA Sciences, Inc., Q4 2023 Earnings Call, Dec 07, 2023
08/12
Earnings Flash (APDN) APPLIED DNA SCIENCES Posts Q4 Revenue $779,736, vs. Street Est of $1.7M
08/12
MT
Applied DNA Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023
08/12
CI
Applied DNA Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
08/12
CI
More news
Applied DNA Sciences : informe des avancées de la collaboration avec Takis Biotech concernant le COVID-19 et de la conception de 4 candidats vaccins LinearDNA™ au stade préclinique
02/20/02
Aktuelle Meldung von Applied DNA Sciences zur COVID-19-Kooperation mit Takis Biotech: vier präklinische LinearDNA™-Impfstoffkandidaten entwickelt
02/20/02
Applied DNA Sciences : GHCL, un acteur mondial du linge de maison, crée "CIRKULARITY", une plateforme de marques inspirée par le linge de lit "REKOOP" en polyester recyclé durable et traçable
30/18/30
Applied DNA Sciences : GHCL, azienda internazionale di tessuti per la casa, crea “CIRKULARITY”, una piattaforma di marchi ispirata da “REKOOP”, biancheria in poliestere riciclato, sostenibile e tracciabile
29/18/29
Applied DNA Sciences : GHCL, weltweiter Anbieter von Heimtextilien, gründet die Markenplattform „CIRKULARITY“, inspiriert von „REKOOP“, der Lösung für nachhaltige, rückverfolgbare, recycelte Polyester-Bettwäsche
29/18/29
More news 1 day -12.60%
1 week -36.32%
Current month -46.71%
1 month -48.95%
3 months -64.87%
6 months -73.66%
Current year -64.58%
More quotes
Managers
Title Age Since
Chief Executive Officer
71
28/05/28
Director of Finance/CFO
47
01/13/01
Chief Tech/Sci/R&D Officer
-
-
Members of the board
Title Age Since
Director/Board Member
74
17/06/17
Director/Board Member
87
07/16/07
Chief Executive Officer
71
28/05/28
More insiders
Date
Price
Change
Volume
26/24/26
4.37
-12.60%
84,077
25/24/25
5
+4.69%
102,239
24/24/24
4.776
-17.66%
61,058
23/24/23
5.8
-12.12%
42,394
22/24/22
6.6
-3.82%
1,791
Delayed Quote
Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Companyâs proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Companyâs Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
More about the company
Last Close Price
4.37
USD
Average target price
45
USD
Spread / Average Target
+929.75%
Consensus
1st Jan change
Capi.
-64.58% 3.77M +0.89% 12.8B -10.29% 7.61B -1.16% 4.51B +5.74% 4.49B -50.70% 3.3B +12.21% 2.73B -16.13% 2.02B -11.50% 1.73B -5.02% 1.64B
Diagnostic & Testing Substances
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1